5 results about "GPR120" patented technology

The invention discloses a strain of lactobacillus acidophilus for treating chronic cerebral ischemia, which is preserved in the China Center for Type Culture Collection (CCTCC) and has the preservation number of CCTCC NO: M 20251505. Animal experiments show that the strain can reduce the death rate of chronic cerebral ischemia model mice and improve neurological impairment, motion coordination and spatial learning and memory ability of the chronic cerebral ischemia model mice. Mechanism research shows that the strain can increase histone acetylation and BDNF secretion by inhibiting the activity of astrocyte HDAC1, and meanwhile, can inhibit an NF-kappa B signal channel and reduce inflammatory factor release by activating a microglial cell GPR120 receptor, so that a neuroprotective effect is achieved through an'intestine-brain axis'. The invention provides a new candidate strain for the development of microbial preparations for preventing and / or treating chronic cerebral ischemia and related cognitive impairment.

The application relates to the technical field of animal nutrition and meat quality regulation, and particularly relates to application of vascular endothelial growth factor B (VEGF-B) in increasing intramuscular fat content of pigs. The content of VEGF-B in pig serum and the expression level of VEGF-B in skeletal muscle tissue are significantly positively correlated with the intramuscular fat content of pigs, so that VEGF-B can be used as a biomarker for predicting the intramuscular fat content of pigs; meanwhile, fish oil rich in n-3 polyunsaturated fatty acids can promote the expression level of VEGF-B by activating G protein-coupled receptor 120 (GPR120), then increase the transvascular endothelial transport of fatty acids in blood vessels to skeletal muscle, and finally increase the intramuscular fat content.

The application discloses application of a GPR120 agonist in preventing or treating intestinal-liver immunological injury induced by poultry acetochlor poisoning. According to the intestinal-liver toxicity of chicken acetochlor, the normal expression of G protein-coupled receptor 120 is mainly changed. Subsequently, programmed cell death occurs in the intestinal tract and the liver, and a large amount of inflammatory factor release is caused; the intestinal-liver axis immunological injury is improved by activating the G protein-coupled receptor 120 in vivo and in vitro, so as to rescue the chicken acetochlor poisoning reaction. The application provides a prevention and treatment basis for poultry acetochlor poisoning immunological injury diseases, provides medical data for developing poultry immunological activity drugs or supplements, and also provides more technical means for developing and utilizing environment-friendly, efficient, targeted and slow-release new veterinary drug preparations.

The invention discloses an application of a GPR120 / FFAR4 agonist TUG-891 in preparation of drugs for treating diabetes and periodontitis syndrome, and by integrating multi-tissue transcriptomics and bioinformatics analysis, it is found for the first time that GPR120 is a key target of diabetes complicated with periodontitis. In-vivo experiments prove that TUG-891 intervention not only can significantly improve systemic metabolic disorders (such as hyperglycemia and dyslipidemia) of diabetic model mice, but also can effectively relieve alveolar bone resorption caused by periodontitis, inhibit osteoclast activity and improve bone microstructure. A further mechanism research shows that the TUG-891 can relieve periodontal local inflammatory response by inhibiting neutrophil extracellular trap formation (NETosis). The invention provides a brand-new targeted therapy strategy for co-disease treatment of diabetes and periodontitis, and has important clinical transformation value.

The present invention provides compositions and pharmaceutical compositions of GPR84 agonists and GPR120 agonists for us in the treatment of obesity and overweight. The invention provides methods of treatment accordingly as well as a kit for use in the treatment of obesity and overweight.